139 related articles for article (PubMed ID: 19223507)
21. T-cell responses to cyclin B1 are not restricted to p53-overexpressing tumors.
von Bergwelt-Baildon MS; Shimabukuro-Vornhagen A; Klein-Gonzalez N; Kondo E
Clin Cancer Res; 2009 Nov; 15(22):7106; author reply 7106-7. PubMed ID: 19903794
[No Abstract] [Full Text] [Related]
22. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients.
Peoples GE; Gurney JM; Hueman MT; Woll MM; Ryan GB; Storrer CE; Fisher C; Shriver CD; Ioannides CG; Ponniah S
J Clin Oncol; 2005 Oct; 23(30):7536-45. PubMed ID: 16157940
[TBL] [Abstract][Full Text] [Related]
23. Increased frequencies of CD8+ T lymphocytes recognizing wild-type p53-derived epitopes in peripheral blood correlate with presence of epitope loss tumor variants in patients with hepatocellular carcinoma.
Cicinnati VR; Zhang X; Yu Z; Ferencik S; Schmitz KJ; Dworacki G; Kaczmarek E; Oldhafer K; Frilling A; Baba HA; Schmid KW; Grosse-Wilde H; Broelsch CE; DeLeo AB; Gerken G; Beckebaum S
Int J Cancer; 2006 Dec; 119(12):2851-60. PubMed ID: 16998881
[TBL] [Abstract][Full Text] [Related]
24. T-cell immunity to the folate receptor alpha is prevalent in women with breast or ovarian cancer.
Knutson KL; Krco CJ; Erskine CL; Goodman K; Kelemen LE; Wettstein PJ; Low PS; Hartmann LC; Kalli KR
J Clin Oncol; 2006 Sep; 24(26):4254-61. PubMed ID: 16908932
[TBL] [Abstract][Full Text] [Related]
25. Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells.
Kao H; Marto JA; Hoffmann TK; Shabanowitz J; Finkelstein SD; Whiteside TL; Hunt DF; Finn OJ
J Exp Med; 2001 Nov; 194(9):1313-23. PubMed ID: 11696596
[TBL] [Abstract][Full Text] [Related]
26. Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma.
Gehring AJ; Ho ZZ; Tan AT; Aung MO; Lee KH; Tan KC; Lim SG; Bertoletti A
Gastroenterology; 2009 Aug; 137(2):682-90. PubMed ID: 19394336
[TBL] [Abstract][Full Text] [Related]
27. Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers.
Imai K; Hirata S; Irie A; Senju S; Ikuta Y; Yokomine K; Harao M; Inoue M; Tsunoda T; Nakatsuru S; Nakagawa H; Nakamura Y; Baba H; Nishimura Y
Clin Cancer Res; 2008 Oct; 14(20):6487-95. PubMed ID: 18927288
[TBL] [Abstract][Full Text] [Related]
28. HER-2 peptides p776 and F7, N-terminal-linked with Ii-Key tetramer (LRMK) help the proliferation of E75-TCR+ cells: The dependency of help on the side chains of LRMK-extended peptide pointed towards the T cell receptor.
Li Y; Ishiyama S; Matsueda S; Tsuda N; Ioannides CG
Oncol Rep; 2008 Jun; 19(6):1445-52. PubMed ID: 18497949
[TBL] [Abstract][Full Text] [Related]
29. Intratumoral cytokines and tumor cell biology determine spontaneous breast cancer-specific immune responses and their correlation to prognosis.
Domschke C; Schuetz F; Ge Y; Seibel T; Falk C; Brors B; Vlodavsky I; Sommerfeldt N; Sinn HP; Kühnle MC; Schneeweiss A; Scharf A; Sohn C; Schirrmacher V; Moldenhauer G; Momburg F; Beckhove P
Cancer Res; 2009 Nov; 69(21):8420-8. PubMed ID: 19843863
[TBL] [Abstract][Full Text] [Related]
30. A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer.
Chianese-Bullock KA; Irvin WP; Petroni GR; Murphy C; Smolkin M; Olson WC; Coleman E; Boerner SA; Nail CJ; Neese PY; Yuan A; Hogan KT; Slingluff CL
J Immunother; 2008 May; 31(4):420-30. PubMed ID: 18391753
[TBL] [Abstract][Full Text] [Related]
31. Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer.
Tilkin AF; Lubin R; Soussi T; Lazar V; Janin N; Mathieu MC; Lefrère I; Carlu C; Roy M; Kayibanda M
Eur J Immunol; 1995 Jun; 25(6):1765-9. PubMed ID: 7615005
[TBL] [Abstract][Full Text] [Related]
32. Heparanase: a new metastasis-associated antigen recognized in breast cancer patients by spontaneously induced memory T lymphocytes.
Sommerfeldt N; Beckhove P; Ge Y; Schütz F; Choi C; Bucur M; Domschke C; Sohn C; Schneeweis A; Rom J; Pollmann D; Leucht D; Vlodavsky I; Schirrmacher V
Cancer Res; 2006 Aug; 66(15):7716-23. PubMed ID: 16885374
[TBL] [Abstract][Full Text] [Related]
33. CD8+ T-cell response against MUC1-derived peptides in gastrointestinal cancer survivors.
Dittmann J; Keller-Matschke K; Weinschenk T; Kratt T; Heck T; Becker HD; Stevanović S; Rammensee HG; Gouttefangeas C
Cancer Immunol Immunother; 2005 Aug; 54(8):750-8. PubMed ID: 15614528
[TBL] [Abstract][Full Text] [Related]
34. Defective gammadelta T-cell function and granzyme B gene polymorphism in a cohort of newly diagnosed breast cancer patients.
Gaafar A; Aljurf MD; Al-Sulaiman A; Iqniebi A; Manogaran PS; Mohamed GE; Al-Sayed A; Alzahrani H; Alsharif F; Mohareb F; Ajarim D; Tabakhi A; Al-Hussein K
Exp Hematol; 2009 Jul; 37(7):838-48. PubMed ID: 19446661
[TBL] [Abstract][Full Text] [Related]
35. Treatment of advanced metastasized breast cancer with bone marrow-derived tumour-reactive memory T cells: a pilot clinical study.
Schuetz F; Ehlert K; Ge Y; Schneeweiss A; Rom J; Inzkirweli N; Sohn C; Schirrmacher V; Beckhove P
Cancer Immunol Immunother; 2009 Jun; 58(6):887-900. PubMed ID: 18998129
[TBL] [Abstract][Full Text] [Related]
36. Cross-priming of cyclin B1, MUC-1 and survivin-specific CD8+ T cells by dendritic cells loaded with killed allogeneic breast cancer cells.
Saito H; Dubsky P; Dantin C; Finn OJ; Banchereau J; Palucka AK
Breast Cancer Res; 2006; 8(6):R65. PubMed ID: 17129372
[TBL] [Abstract][Full Text] [Related]
37. The shaping of a polyvalent and highly individual T-cell repertoire in the bone marrow of breast cancer patients.
Sommerfeldt N; Schütz F; Sohn C; Förster J; Schirrmacher V; Beckhove P
Cancer Res; 2006 Aug; 66(16):8258-65. PubMed ID: 16912206
[TBL] [Abstract][Full Text] [Related]
38. CD8+ T cells reactive to survivin antigen in patients with multiple myeloma.
Grube M; Moritz S; Obermann EC; Rezvani K; Mackensen A; Andreesen R; Holler E
Clin Cancer Res; 2007 Feb; 13(3):1053-60. PubMed ID: 17289902
[TBL] [Abstract][Full Text] [Related]
39. Toward the development of multi-epitope p53 cancer vaccines: an in vitro assessment of CD8(+) T cell responses to HLA class I-restricted wild-type sequence p53 peptides.
Sakakura K; Chikamatsu K; Furuya N; Appella E; Whiteside TL; Deleo AB
Clin Immunol; 2007 Oct; 125(1):43-51. PubMed ID: 17631051
[TBL] [Abstract][Full Text] [Related]
40. No evidence for circulating HuD-specific CD8+ T cells in patients with paraneoplastic neurological syndromes and Hu antibodies.
de Beukelaar JW; Verjans GM; van Norden Y; Milikan JC; Kraan J; Hooijkaas H; Sintnicolaas K; Gratama JW; Sillevis Smitt PA
Cancer Immunol Immunother; 2007 Sep; 56(9):1501-6. PubMed ID: 17597332
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
